Antibody evolution immunogens
US-2015366961-A1 · Dec 24, 2015 · US
Optimized hiv envelope gene and expression thereof
US2019201522A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019201522-A1 |
| Application number | US-201916291073-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 4, 2019 |
| Priority date | Oct 27, 2014 |
| Publication date | Jul 4, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
First claim
Opening claim text (preview).
What is claimed is: 1 . A viral vector containing and expressing a nucleic acid encoding an optimized human immunodeficiency virus (HIV) immunogen, wherein the HIV immunogen is a Clade A Env-F hybrid based on BG505. 2 . The vector of claim 1 , wherein the nucleic acid comprises the nucleic acid sequence of FIG. 27 . 3 . The vector of claim 1 , wherein the nucleic acid encodes an amino acid sequence of the HIV immunogen comprises the amino acid sequence of FIG. 27 . 4 . The vector of claim 1 , wherein the vector is a canine distemper virus (CDV) or a vesicular stomatitis virus (VSV) vector. 5 . A cell transfected with the vector of claim 1 . 6 . The cell of claim 5 wherein the cell is a Vero cell. 7 . A method for eliciting an immune response against HIV comprising administering an effective amount of the vector of claim 1 to a mammal in need thereof. 8 . The method of claim 7 further comprising administering an adjuvant. 9 . The method of claim 8 , wherein the adjuvant is comprised of an acrylic polymer.
Assignees
Inventors
Classifications
Immunostimulants · CPC title
for HIV · CPC title
from viruses · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
viral genome or elements thereof as genetic vector · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019201522A1 cover?
- The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative
- What technology area does this patent fall under?
- Primary CPC classification A61K39/21. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jul 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).